Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
Cabozantinib, as compared with placebo, significantly improved progression-free survival in patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors. Adverse events were consistent with the known safety profile of cabozantinib. (Funded by the National Cancer Institute and others; CABINET ClinicalTrials.gov number, NCT03375320.).
Authors
- Elise C. Kohn (ORCID: https://orcid.org/0000-0002-8631-9762)
- Susan M. Geyer (ORCID: https://orcid.org/0009-0002-5649-6909)
- Jared David Acoba (ORCID: https://orcid.org/0000-0003-4145-8010)
- Bernard Tawfik (ORCID: https://orcid.org/0000-0002-4380-2471)
- Nikolaos A. Trikalinos (ORCID: https://orcid.org/0000-0001-8611-2182)
- Michael V. Knopp (ORCID: https://orcid.org/0000-0001-9543-2962)
- Arvind N. Dasari (ORCID: https://orcid.org/0000-0001-5271-9744)
- Matthew H. Kulke (ORCID: https://orcid.org/0000-0001-8556-3977)
- Edward M. Wolin (ORCID: https://orcid.org/0000-0003-3992-8722)
- Spencer C. Behr (ORCID: https://orcid.org/0000-0001-9400-0543)
- Tyler Zemla (ORCID: https://orcid.org/0009-0005-2390-3557)
- Jeffrey A. Meyerhardt (ORCID: https://orcid.org/0000-0002-1120-0898)
- Bhavana Konda (ORCID: https://orcid.org/0000-0002-9099-5990)
- Namrata Vijayvergia (ORCID: https://orcid.org/0000-0001-6469-4759)
- Nitya Raj (ORCID: https://orcid.org/0000-0002-1385-9995)
- Shagufta Shaheen (ORCID: https://orcid.org/0000-0001-8385-1641)
- Jennifer A. Chan (ORCID: https://orcid.org/0000-0001-9798-1551)
- Jonathan Strosberg (ORCID: https://orcid.org/0000-0001-8405-218X)
- Fang‐Shu Ou (ORCID: https://orcid.org/0000-0003-1267-8735)
- Eileen Mary O'Reilly (ORCID: https://orcid.org/0000-0002-8076-9199)
- Ardaman P. Shergill (ORCID: https://orcid.org/0000-0002-8244-2704)
- Sydney Pulsipher
- Amylou Constance Dueck (ORCID: https://orcid.org/0000-0002-9912-1085)
- Þorvarður R. Hálfdánarson (ORCID: https://orcid.org/0000-0001-8460-1257)
Institutions
- Boston University (US)
- University of Hawaiʻi at Mānoa (US)
- Boston Medical Center (US)
- Fox Chase Cancer Center (US)
- Mayo Clinic (US)
- University of Hawaii System (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of New Mexico (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Alliance for Clinical Trials in Oncology (US)
- Moffitt Cancer Center (US)
- University of Chicago (US)
- Cancer Center of Hawaii (US)
- Mount Sinai Medical Center (US)
- Sidney Kimmel Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- National Cancer Institute (US)
- New Mexico Cancer Center (US)
- University of Hawaii Cancer Center
- UNM Comprehensive Cancer Center
- The Ohio State University (US)
- University of Cincinnati (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1056/nejmoa2403991
- Citations
- 111
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 42.92
Funders
- American College of Radiology Imaging Network
- Exelixis
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
- National Institutes of Health
- National Cancer Institute